Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Multiple-Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Next Previous
X
Search
Trial Profile

An Open-Label Multiple-Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ersodetug (Primary)
  • Indications Congenital hyperinsulinism; Hypoglycaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms RIZE
  • Sponsors Rezolute; XOMA

    • Most Recent Events

    • 23 Apr 2024 According to a Rezolute media release, data from this study will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.
    • 23 Jan 2024 According to a Rezolute media release, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). The Innovation Passport designation was granted based on the substantial unmet medical need in this condition and the potential for RZ358 to benefit patients as evidenced by the Phase 2 RIZE study.
    • 17 Oct 2023 According to a Rezolute media release, company announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) eligibility to RZ358 for the treatment of congenital hyperinsulinism based on the data from the RIZE study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top